Lauren Massaro

The therapy’s Prescription Drug User Fee Act date has been set for July 26, 2025.

Two posters presented at the annual meeting of the American College of Chest Physicians, CHEST 2024, offered insights into the accurate diagnosis and appropriate treatment of ACOS.

Adherence interventions and comprehensive reviews can reduce health care costs, boost revenue, and improve patient outcomes.

Florida-based pharmacist Brad Phillips, PharmD, BCACP, speaks to the importance of pre-planning, emergency refills, medication storage, and post-storm safety measures to ensure medication security during hurricanes.

Research presented at CHEST 2024 outlined the heart failure risks associated with COVID-19 infection and emphasized the importance of vaccination to prevent adverse outcomes.

Whether patients present with complaints of an aching muscle from a workout or a sudden twinge in the back, consider recommending these topical analgesics.

In case you missed it, this week we had stories about the availability of the first liquid nonstimulant for ADHD, pharmacy technicians as "vaccine champions," SGLT2i's heart-healthy benefits, and more.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Social pressures, physiological changes, mental health challenges, and burnout all complicate diabetes management among adolescents.

Many public health officials aren’t surprised by the decline in vaccine coverage, although its underlying causes present unique challenges.

See what’s trending in pharmacy with a preview of the Drug Topics September/October issue.

The Heart Failure Society of America 2024 Annual Meeting featured presentations exploring the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for patients with heart failure.

Research presented at the Heart Failure Society of America 2024 Annual Meeting demonstrated that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduced cardiovascular events in patients without diabetes.

Investigators suggested that the future cost-effectiveness of respiratory syncytial virus (RSV) vaccination could be improved through lower vaccine prices and longer-lasting protection.

In case you missed it, this week we had stories about pharmacists overcoming substance use disorder, the first new treatment approved for schizophrenia in decades, the Senate-Novo Nordisk hearing on semaglutide prices, and more.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

The approval of xanomeline and trospium chloride (Cobenfy) from Bristol Myers Squibb represents a “transformative moment in the treatment of schizophrenia.”

In the TEMPO-1 trial, both tavapadon doses effectively reduced motor symptoms in patients with early-stage Parkinson's disease.

Study findings raise concern about increased pain and disability, poorer pain self-management, and impaired quality of life during adolescence that can continue into young adulthood.

Higher doses of buprenorphine may also be more effective against the increasing prevalence of fentanyl in the opioid crisis.

“Pharmacies are processing prescriptions, our supply chain is fully operational, and most importantly, the first patients are now receiving neffy,” said Eric Karas, CCO of ARS Pharmaceuticals.

Initiatives such as media campaigns and legislative rulings by the agencies have likely contributed to the decline.

In case you missed it, this week we had news about end-of-year PBM reform on the horizons, cebranopadol as a transformational new pain therapy, success in co-administration of RSV and shingles vaccines, and more.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Stephanie Sober, MD, MSHP, shares insights into the research that led to Opill’s FDA approval and its implications for women’s access to contraception.

“By encouraging active self-management using health coaching principles, the WalkBack intervention might be able to reduce the prevalence of recurrent low back pain and associated burden on health care systems,” wrote investigators.

A co-administration option for both vaccinations can increase the likelihood of older adults completing the vaccination series and improve health outcomes for the patient population.

Mark Garofoli combined personal anecdotes with professional expertise to deliver a compelling presentation on kidney stone pain at this year’s PAINWeek National Conference.

Lebrikizumab-lbks is a targeted treatment that addresses the root cause of atopic dermatitis; by reducing inflammation throughout the body, it can help alleviate the dry, itchy, and irritated skin that often characterizes the condition.

In case you missed it, this week we had news about novel treatments for dry eye disease, art therapy and mental health, abdominal fat's role in pain, and more.